LFG
HUMA icon

Larson Financial Group’s Humacyte HUMA Stock Holding History

Larson Financial Group’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9 Hold
12
– – ﹤0.01% 3734
2026
Q1 		$7 Hold
12
– – ﹤0.01% 3612
2025
Q4 		$12 Hold
12
– – ﹤0.01% 3423
2025
Q3 		$21 Buy
+12
New +$24 ﹤0.01% 3393

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Larson Financial Group's HUMA Position: Q2 2026 in Review

Larson Financial Group held its Humacyte (HUMA) position steady in Q2 2026 at 12 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

Larson Financial Group first reported a position in HUMA in Q3 2025 and has held it in 4 quarters since. The position peaked at $21 in Q3 2025. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Larson Financial Group held 12 shares of Humacyte worth $9 as of Q2 2026.
  • Larson Financial Group left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3734 holding.
  • Larson Financial Group first reported a position in Humacyte in Q3 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Humacyte position peaked at $21 in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.